A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)
NCT04476017
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
18
Enrollment
INDUSTRY
Sponsor class
Conditions
Parkinson Disease
Cognitive Dysfunction
Interventions
DRUG:
SAGE-718
Sponsor
Supernus Pharmaceuticals, Inc.